Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2019 Dec;266(12):3038-3046.
doi: 10.1007/s00415-019-09527-2. Epub 2019 Sep 9.

How satisfied are cervical dystonia patients after 3 years of botulinum toxin type A treatment? Results from a prospective, long-term observational study

Carlo Colosimo  1 , David Charles  2 , Vijay P Misra  3 , Pascal Maisonobe  4 , Savary Om  4 ; INTEREST IN CD2 study group
Collaborators, Affiliations
Observational Study

How satisfied are cervical dystonia patients after 3 years of botulinum toxin type A treatment? Results from a prospective, long-term observational study

Carlo Colosimo et al. J Neurol. 2019 Dec.

Erratum in

Abstract

Background: Patients with cervical dystonia (CD) typically require regular injections of botulinum toxin to maintain symptomatic control. We aimed to document long-term patient satisfaction with CD symptom control in a large cohort of patients treated in routine practice.

Methods: This was a prospective, international, observational study (NCT01753349) following the course of adult CD treated with botulinum neurotoxin type A (BoNT-A) over 3 years. A comprehensive clinical assessment status was performed at each injection visit and subjects reported satisfaction in two ways: satisfaction with symptom control at peak effect and at the end of treatment cycle.

Results: Subject satisfaction remained relatively stable from the first to the last injection visit. At 3 years, 89.9% of subjects reported satisfaction with symptom control at peak effect and 55.6% reported satisfaction with symptom control at end of treatment cycle. By contrast, objective ratings of CD severity showed an overall reduction over 3 years. Mean ± SD Toronto Western Spasmodic Rating Scale (TWSTRS) Total scores (clinician assessed at end of treatment cycle) decreased from 31.59 ± 13.04 at baseline to 24.49 ± 12.43 at 3 years (mean ± SD reduction from baseline of - 6.97 ± 11.56 points). Tsui scale scores also showed gradual improvement; the percent of subjects with a tremor component score of 4 reduced from 12.4% at baseline to 8.1% at 3 years.

Conclusions: Despite objective clinical improvements over 3 years, subject satisfaction with symptom control remained relatively constant, indicating that factors other than symptom control also play a role in patient satisfaction.

Keywords: Botulinum toxin; Cervical dystonia; Observational study; Satisfaction; Treatment.

PubMed Disclaimer

Conflict of interest statement

Prof C Colosimo reports consultancy for Ipsen, Merz, Abbvie, BIAL, Zambon and UCB. Vanderbilt University receives income from Abbott, Allergan, Boston Scientific, Ipsen, Lundbeck, Merz, Medtronic, and US WorldMeds for research or educational programs led by Dr D Charles. Dr D Charles receives income from Allergan, Ipsen, Revance, US WorldMeds, and the Alliance for Patient Access for education or consulting services. Dr VP Misra report consultancy for Ipsen. P Maisonobe & Dr S Om are Ipsen employees.

Figures

Fig. 1
Fig. 1
Patient flow through the study
Fig. 2
Fig. 2
Subject satisfaction with symptom control and TWSTRS Total scores over 3 years. Baseline satisfaction was only assessed in patients who had previously been treated with botulinum toxin prior to study entry. CI confidence interval, TWSTRS Toronto Western Spasmodic Rating Scale
See this image and copyright information in PMC

References

    1. Stacy M. Epidemiology, clinical presentation, and diagnosis of cervical dystonia. Neurol Clin. 2008;26(Suppl 1):23–42. doi: 10.1016/S0733-8619(08)80003-5. - DOI - PubMed
    1. Chan J, Brin MF, Fahn S. Idiopathic cervical dystonia: clinical characteristics. Mov Disord. 1991;6(2):119–126. doi: 10.1002/mds.870060206. - DOI - PubMed
    1. Defazio G, Jankovic J, Giel JL, Papapetropoulos S. Descriptive epidemiology of cervical dystonia. Tremor Other Hyperkinet Mov (N Y) 2013 doi: 10.7916/D80C4TGJ. - DOI - PMC - PubMed
    1. Ben-Shlomo Y, Camfield L, Warner T. What are the determinants of quality of life in people with cervical dystonia? J Neurol Neurosurg Psychiatry. 2002;72(5):608–614. doi: 10.1136/jnnp.72.5.608. - DOI - PMC - PubMed
    1. Pekmezovic T, Svetel M, Ivanovic N, Dragasevic N, Petrovic I, Tepavcevic DK, Kostic VS. Quality of life in patients with focal dystonia. Clin Neurol Neurosurg. 2009;111(2):161–164. doi: 10.1016/j.clineuro.2008.09.023. - DOI - PubMed

Publication types

Substances